C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 295/04 (2006.01) A61K 31/495 (2006.01) C07D 213/72 (2006.01) C07D 213/74 (2006.01) C07D 213/82 (2006.01) C07D 215/38 (2006.01) C07D 237/20 (2006.01) C07D 241/26 (2006.01) C07D 241/44 (2006.01) C07D 295/03 (2006.01) C07D 295/033 (2006.01) C07D 295/073 (2006.01) C07D 295/092 (2006.01) C07D 295/096 (2006.01) C07D 295/112 (2006.01) C07D 401/04 (2006.01) C07D 471/04 (2006.01) C07D 491/04 (2006.01)
Patent
CA 2474214
Novel aryl- and heteroarylpiperazines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.
L'invention concerne de nouvelles aryl- et hétéroarylpiperazines, l'utilisation de ces composés comme compositions pharmaceutiques, les compositions pharmaceutiques comprenant les composés ainsi qu'une méthode thérapeutique utilisant ces composés et compositions. Les composés font preuve d'une forte affinité de liaison sélective avec le récepteur de l'histamine H3 indiquant une activité antagoniste du récepteur H3, agoniste inverse ou agoniste. Par conséquent, les composés sont utilisés dans le traitement de maladies et de troubles associés au récepteur de l'histamine H3.
Doerwald Florencio Zaragoza
Hohlweg Rolf
Peschke Bernd
Pettersson Ingrid
Stephensen Hendrik
Dimock Stratton Llp
High Point Pharmaceuticals Llc
Novo Nordisk A/s
LandOfFree
Novel aryl- and heteroarylpiperazines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel aryl- and heteroarylpiperazines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel aryl- and heteroarylpiperazines will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1419181